Antifungal Drugs Market | Global Market Opportunities & Strategies to 2025


Posted October 3, 2019 by Shristi

Global Antifungal Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025
 
Analyst Speak:

“The Global Antifungal Drugs Market growing at a significant CAGR over the seven years of forecast years 2019-2025 to reach US$ 18,643.8 Mn by 2025 owing to grow in prevalence of fungal diseases among the population”

The global antifungal drugs market was valued at US$ XX Mn in 2018 and increasing at a significant growth rate over the forecast years due to increase in the prevalence of fungal diseases such as aspergillosis, candidiasis, dermatophytosis and others. For instance, according to Center for Diseases Control and Prevention, approximately 1 Mn affected with cryptococcal meningitis, a brain infection caused by fungus around the globe. Moreover, surge in incidence of hospital acquired infection, increase in the R&D expenditure for the development of newer antifungal drugs, unhygienic environments in underdeveloped countries, and rise in healthcare expenditure are propel the global antifungal drugs market over the forecast years. However, alternative treatment procedures for the fungal infections, patent expiry of branded drugs, and entry of generics into market are hamper the growth of antifungal drugs market over the forecast timeframe

Global antifungal drugs market segmented on the basis of drug class, disease type, route of administration, distribution channel, and region

Avail Sample Report of the Market @ https://www.precisionbusinessinsights.com/request-sample?product_id=15770

Azoles Dominate the Global Antifungal Drugs Market

Based on the drug class, global antifungal drugs market segmented into azoles, echinocandins, polyenes, allylamines, and others. Among all the drug classes, azoles dominated the global antifungal drugs market in 2018 and the same trend is expected over the forecast years owing to launch of newer therapeutics into the market. For instance, in November 2017, Pfizer partnered with Basilea to launch antifungal drug Cresemba (Isavuconazole) used in the treatment of mucormycosis infection in adults. Moreover, increase in the awareness among the population about antifungal drugs also surge the global antifungal drugs market over the future years.

North America Leads the Global Antifungal Drugs market

PBI’s global antifungal drugs market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America accounted for larger revenue share through 2014-2018 and expected to dominate over 2019-2025 owing to surge in the incidence of fungal diseases in U.S. and Canada. For instance, according to CDC, approximately 25,000 people diagnosed with candidemia each year. Moreover, favorable reimbursement policies, increase in the R&D activities for the development of newer therapeutics, and surge in healthcare expenditure are bolster the market over the forecast years. Asia Pacific antifungal drugs market projected to exhibit significant growth due to large patient pool, rapid growth in population in India and China, and launch of generics in the regions.

Launch of newer products, frequent product approvals, and strategic alliances are the key strategies adopted by market players

Global antifungal drugs market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance. In December 2016, Dr. Reddy’s launched Nystatin and Triamcinolone Acetonide Cream, a generic antifungal product for the treatment of cutaneous candidiasis.

Key player’s profiles in the report are AbbVie, Inc., Merck & Co. Inc., Amgen, Inc., Novartis AG, Sanofi S.A., Eisai Co., Ltd., GlaxoSmithKline plc, Dr. Reddy’s Laboratories, Enzon Pharmaceuticals, Inc., and Basilea Pharmaceuticals, Ltd.,

For More Information @ https://www.precisionbusinessinsights.com/market-reports/global-anti-fungal-drugs-market/

Precision Business Insights (PBI) in its report titled “Global Antifungal Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

Detailed Segmentation

By Drug Class

Azoles
Polyenes
Echinocandins
Allylamines
Others
Disease Type

Aspergillosis
Candidiasis
Dermatophytosis
Others
Route of Administration

Oral
Parenteral
Topical
By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography

North America

US
Canada
Europe

Germany
France
UK
Italy
Spain
Russia
Poland
Rest of Europe
Asia-Pacific

Japan
China
India
Australia & New Zealand
ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
South Korea
Rest of Asia-Pacific
Latin America

Brazil
Mexico
Argentina
Rest of Latin America
Middle East and Africa (MEA)

Gulf Cooperation Council (GCC) Countries
Israel
South Africa
Rest of MEA
About Us:
 
Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.
 
Contact Us:
 
Shreya Paul
Senior Business Development Executive
Email @ [email protected]
Call @ +1-866-598-1553
Precision Business Insights
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Precision business Insights
Country India
Categories Health
Tags antifungal drugs market , antifungal drugs market forecast , antifungal drugs market growth
Last Updated October 3, 2019